Daewon Pharmaceutical Co., Ltd. (KRX:003220)
South Korea · Delayed Price · Currency is KRW 7,880.00
+120.00 (1.55%)
Aug 28, 2026, 3:30 PM KST
Daewon Pharmaceutical Revenue
Daewon Pharmaceutical had revenue of 152.83B KRW in the quarter ending June 30, 2026, with 6.24% growth. This brings the company's revenue in the last twelve months to 614.64B, up 1.83% year-over-year. In the year 2025, Daewon Pharmaceutical had annual revenue of 605.43B with 1.22% growth.
Revenue (ttm)
614.64B
Revenue Growth
+1.83%
P/S Ratio
0.27
Revenue / Employee
497.28M
Employees
1,236
Market Cap
168.90B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 605.43B | 7.27B | 1.22% |
| Dec 31, 2024 | 598.16B | 71.21B | 13.51% |
| Dec 31, 2023 | 526.95B | 48.07B | 10.04% |
| Dec 31, 2022 | 478.88B | 124.71B | 35.21% |
| Dec 31, 2021 | 354.18B | 45.68B | 14.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chong Kun Dang Holdings | 961.64B |
| Ilyang Pharmaceutical Co.,Ltd | 277.96B |
| Whan In Pharm | 273.47B |
| JW Lifescience | 253.71B |
| Daihan Pharmaceutical | 216.55B |
| REYON Pharmaceutical | 143.37B |
| Hana Pharm | 139.33B |
| Hyundai Pharmaceutical | 108.14B |